Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated C and is the 61st ranked industry out of 146 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
CDNA	CAREDX INC	$1.46B	51,659,481	77.21%	22.79%	Net Selling	Net Selling
BLLN	BILLIONTOONE INC	$5.43B	45,995,484	24.65%	18.94%	Net Buying	Net Selling
NEO	NEOGENOMICS INC	$1.89B	130,211,780	73.34%	26.66%	Net Selling	Net Selling
A	AGILENT TECHNOLOGIES INC	$37.04B	282,431,944	89.65%	1.28%	Net Buying	Net Selling
ILMN	ILLUMINA INC	$29.01B	151,300,000	92.35%	7.65%	Net Selling	Net Selling
SHC	SOTERA HEALTH CO	$5.14B	285,166,994	96.63%	3.24%	Net Selling	Net Selling
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$11.01B	48,167,730	96.87%	3.13%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$23.28B	82,000,000	95.42%	1.62%	Net Selling	Net Selling
NEOG	NEOGEN CORP	$2.04B	217,673,041	97.92%	2.08%	Net Buying	Net Buying
WAT	WATERS CORP	$36.81B	98,185,855	95.13%	4.87%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$44.98B	78,882,997	90.71%	1.81%	Net Buying	Net Selling
IQV	IQVIA HOLDINGS INC	$34.75B	166,900,000	53.00%	47.00%	Net Selling
MEDP	MEDPACE HOLDINGS INC	$15.60B	28,559,689	26.94%	73.06%	Net Selling	Net Buying
DGX	QUEST DIAGNOSTICS INC	$23.51B	110,696,429	92.62%	1.82%	Net Selling	Net Selling
BDSX	BIODESIX INC	$205.61M	10,108,580	8.90%	91.10%	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$191.99B	371,621,465	89.34%	0.93%	Net Buying	Net Selling
DHR	DANAHER CORP	$137.44B	707,770,627	75.76%	24.24%	Net Selling	Net Buying
RVTY	REVVITY INC	$12.50B	111,559,773	97.27%	2.73%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$26.18B	20,207,601	95.32%	4.68%	Net Buying
LAB	STANDARD BIOTOOLS INC	$350.94M	390,368,119	48.55%	51.45%	Net Buying	Net Selling
ICLR	ICON PLC	$12.92B	76,601,538	99.48%	0.52%
PRPO	PRECIPIO INC	$46.47M	1,787,372	0.62%	99.38%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$553.47M	94,448,210	95.01%	4.99%	Net Selling	Net Selling
NTRA	NATERA INC	$40.28B	143,215,382	80.72%	19.28%	Net Selling	Net Selling
GH	GUARDANT HEALTH INC	$21.60B	132,599,929	69.97%	30.03%	Net Selling	Net Selling
BNR	BURNING ROCK BIOTECH LTD	$113.03M	105,195,874	1.63%	18.67%	Net Buying	Net Buying
QGEN	QIAGEN NV	$8.01B	206,801,000	60.68%	0.00%
QUCY	QUANTUM CYBER NV	$19.65M	14,661,169	2.06%	14.32%	Net Buying
TWST	TWIST BIOSCIENCE CORP	$5.67B	62,271,314	89.06%	10.94%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$784.91M	139,663,680	58.10%	41.90%	Net Selling	Net Selling
GRAL	GRAIL INC	$2.95B	42,916,593	80.86%	19.14%	Net Selling	Net Buying
OPK	OPKO HEALTH INC	$1.13B	755,092,256	20.76%	79.24%	Net Buying
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$159.19M	32,290,167	18.52%	81.48%	Net Buying	Net Buying
RDNT	RADNET INC	$5.33B	78,634,236	71.30%	28.70%	Net Selling	Net Selling
PRE	PRENETICS GLOBAL LTD	$285.14M	16,982,575	11.72%	8.16%
XGN	EXAGEN INC	$115.97M	24,159,839	40.04%	46.87%	Net Selling
BIAF	BIOAFFINITY TECHNOLOGIES INC	$3.76M	4,534,906	4.79%	95.21%
STIM	NEURONETICS INC	$107.86M	69,587,840	54.58%	45.42%	Net Selling	Net Buying
VNRX	VOLITIONRX LTD	$11.66M	8,330,270	35.53%	64.47%	Net Buying
PSNL	PERSONALIS INC	$1.46B	104,721,098	69.77%	30.23%	Net Buying	Net Buying
CSTL	CASTLE BIOSCIENCES INC	$722.76M	30,329,952	85.75%	14.25%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$596.98M	28,400,623	57.05%	42.95%	Net Selling	Net Selling
ISPC	ISPECIMEN INC	$3.45M	1,437,157	7.61%	92.39%
TRIB	TRINITY BIOTECH PLC	$7.47M	374,206,640	0.29%	0.13%
SERA	SERA PROGNOSTICS INC	$78.71M	39,158,725	50.93%	25.28%	Net Selling	Net Selling
MDXH	MDXHEALTH SA	$2.41M	51,364,520	40.85%	59.15%
MBAI	CHECK-CAP LTD	$8.00M	7,020,502	0.42%	0.00%
XWEL	XWELL INC	$8.02M	8,444,266	1.72%	98.28%
DRIO	DARIOHEALTH CORP	$51.77M	7,312,398	5.71%	94.29%	Net Buying
BNBX	BNB PLUS CORP	$2.52M	7,197,228	5.03%	94.97%
ADVB	ADVANCED BIOMED INC	$7.39M	1,382,133	0.00%	0.00%
NDRA	ENDRA LIFE SCIENCES INC	$6.29M	1,270,077	6.57%	93.43%	Net Buying

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Jul 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #1 top diagnostic & research stock out of 52 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 34, which is 7 points higher than the diagnostic & research industry average of 27.

CDNA passed 11 out of 33 due diligence checks and has average fundamentals. Caredx has seen its stock return 53.44% over the past year, overperforming other diagnostic & research stocks by 30 percentage points.

Caredx has an average 1 year price target of $24.50, a downside of -13.46% from Caredx's current stock price of $28.31.

Caredx stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Caredx, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Billiontoone (NASDAQ:BLLN)

Billiontoone (NASDAQ:BLLN) is the #2 top diagnostic & research stock out of 52 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Billiontoone (NASDAQ:BLLN) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Billiontoone (NASDAQ:BLLN) has a Due Diligence Score of 11, which is -16 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates BLLN as a "B".

BLLN passed 3 out of 33 due diligence checks and has weak fundamentals.

Billiontoone has an average 1 year price target of $117.50, a downside of -0.46% from Billiontoone's current stock price of $118.04.

Billiontoone stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Billiontoone, 75% have issued a Strong Buy rating, 0% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Neogenomics (NASDAQ:NEO)

Neogenomics (NASDAQ:NEO) is the #3 top diagnostic & research stock out of 52 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Neogenomics (NASDAQ:NEO) is: Value: C, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: C.

Neogenomics (NASDAQ:NEO) has a Due Diligence Score of 28, which is 1 points higher than the diagnostic & research industry average of 27.

NEO passed 9 out of 33 due diligence checks and has average fundamentals. Neogenomics has seen its stock return 98.36% over the past year, overperforming other diagnostic & research stocks by 75 percentage points.

Neogenomics has an average 1 year price target of $15.60, an upside of 7.59% from Neogenomics's current stock price of $14.50.

Neogenomics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Neogenomics, 60% have issued a Strong Buy rating, 40% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 5.91%, which is 4 percentage points higher than the diagnostic & research industry average of 1.46%.

Qiagen Nv's dividend payout ratio of 142.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.16%, which is the same as the diagnostic & research industry average of 1.46%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 35.6% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.01%, which is the same as the diagnostic & research industry average of 1.46%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 25.4% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.87% in the last day, and up 2.42% over the last week. Xwell was the among the top losers in the diagnostics & research industry, dropping -12.84% yesterday.

XWELL shares are trading lower. The company announced a definitive agreement to divest its XpresSpa Holdings and XpresTest businesses for $13 million.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 14, which is 4 points higher than the diagnostic & research industry average of 10. It passed 1 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -18.54% in the past year. It has underperformed other stocks in the diagnostic & research industry by -42 percentage points.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Agilent Technologies has a valuation score of 0, which is -10 points higher than the diagnostic & research industry average of 10. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates A a Valuation Rating of "B".

Agilent Technologies's stock has gained 9.97% in the past year. It has underperformed other stocks in the diagnostic & research industry by -13 percentage points.

3. Danaher (NYSE:DHR)

Danaher (NYSE:DHR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Danaher has a valuation score of 14, which is 4 points higher than the diagnostic & research industry average of 10. It passed 1 out of 7 valuation due diligence checks.

Danaher's stock has dropped -2.73% in the past year. It has underperformed other stocks in the diagnostic & research industry by -26 percentage points.

Are diagnostic & research stocks a good buy now?

48.78% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 6.59% over the next year.

2.33% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 11.63% of diagnostic & research stocks are rated B (Buy), 72.09% are rated C (Hold), 13.95% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 12.71x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Caredx (NASDAQ:CDNA)

2. Billiontoone (NASDAQ:BLLN)

3. Neogenomics (NASDAQ:NEO)

1. Qiagen Nv (NYSE:QGEN)

2. Quest Diagnostics (NYSE:DGX)

3. Labcorp Holdings (NYSE:LH)

1. Qiagen Nv (NYSE:QGEN)

2. Agilent Technologies (NYSE:A)

3. Danaher (NYSE:DHR)

Company

Stock Tools

Stock Ideas